• Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G., Tura, S. (1999) The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. British Journal of Haematology, 104, 730737.
  • Cain, W.C., Stuart, R.W., Lefkowitz, D.L., Starnes, J.D., Margolin, S., Lefkowitz, S.S. (1998) Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. International Journal of Immunopharmacology, 20, 685695.DOI: 10.1016/s0192-0561(98)00042-3
  • Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I., Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 10131018.
  • Gurujeyalakshmi, G., Hollinger, M.A., Giri, S.N. (1999) Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. American Journal of Physiology, 276, L311L318.
  • Iyer, S.N., Gurujeyalakshmi, G., Giri, S.N. (1999) Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. Journal of Pharmacology and Experimental Therapeutics, 291, 367373.
  • Kaneko, M., Inoue, H., Nakazawa, R., Azuma, N., Suzuki, M., Yamauchi, S., Margolin, S.B., Tsubota, K., Saito, I. (1998) Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clinical and Experimental Immunology, 113, 7276.
  • Kanfer, E.J., Price, C.M., Gordon, A.A., Barrett, A.J. (1993) The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders. European Journal of Haematology, 50, 250254.
  • Martyre, M.C., Magdelenat, H., Bryckaert, M.C., Laine-Bidron, C., Calvo, F. (1991) Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor beta in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 77, 8086.
  • Martyre, M.C., Romquin, N., Le Bousse-Kerdiles, M.C., Chevillard, S., Benyahia, B., Dupriez, B., Demory, J.L., Bauters, F. (1994) Transforming growth factor beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. British Journal of Haematology, 88, 916.
  • Mesa, R.A., Hanson, C.A., Rajkumar, S.V., Schroeder, G., Tefferi, A. (2000) Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood, 96, 33743380.
  • Raghu, G., Johnson, W.C., Lockhart, D., Mageto, Y. (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. American Journal of Respiratory and Critical Care Medicine, 159, 10611069.
  • Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia. New England Journal of Medicine, 342, 12551265.